Hematology

Measured and unmeasured costs can have a significant impact on outcomes for patients with cancer.

A new study conducted by researchers at Kaiser Permanente has found that a considerable number of working-age adults who survive cancer and its toxic treatments, end up with substantial medical debts or declare bankruptcy.

Early trial shows potential of stem cell transplant combined and high-dose chemotherapy.

Researchers explore alternate treatment for chronic lymphocytic leukemia.

Global AML market forecast to reach nearly a billion dollars by 2024.

Ibrutinib is significantly more effective than chlorambucil in chronic lymphocytic leukemia.

Revenue not expected to maintain pace of current immunology treatments.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.

Vistogard treats patients who develop life-threatening toxicities within days of receiving cancer drugs.

Bendeka was approved for indolent B-cell non-Hodgkin lymphoma that progressed during or within 6 months of treatment with a rituximab regimen.

Trial data shows positive results across a range of difficult-to-treat patients with MM.

Top news of the week in cancer drug development.

Researchers target how cancer cells avoid treatment.

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

Addition of midostaurin to chemotherapy shows promise in patients with AML.

Experts provide unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma.

Addition of bortezomib to lenalidomide and low-dose dexamethasone therapy extends disease control.

Anemia caused by chemotherapy for lymphoid malignancies improved in patients with non-Hodgkin's lymphoma and multiple myeloma.

Epoetin alfa biosimilar shows promise in early study.

Empliciti combination decreased disease progression risk by 30%.

Reolysin plus bortezomib and dexamethasone treats patients with relapsed or refractory multiple myeloma.

Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide and dexamethasone.

Molecular mechanisms behind acute myeloid leukemia may offer a new target for drug development.

Novel drug shows promise in chronic lymphocytic leukemia and non-Hodgkin lymphoma refractory or resistant to current chemotherapies.

Daratumumab is a single agent for multiple myeloma in patients who previously received at least 3 lines of therapy.